218 related articles for article (PubMed ID: 18537643)
1. Voltage-gated sodium channels in neurological disorders.
Chahine M; Chatelier A; Babich O; Krupp JJ
CNS Neurol Disord Drug Targets; 2008 Apr; 7(2):144-58. PubMed ID: 18537643
[TBL] [Abstract][Full Text] [Related]
2. Neurological perspectives on voltage-gated sodium channels.
Eijkelkamp N; Linley JE; Baker MD; Minett MS; Cregg R; Werdehausen R; Rugiero F; Wood JN
Brain; 2012 Sep; 135(Pt 9):2585-612. PubMed ID: 22961543
[TBL] [Abstract][Full Text] [Related]
3. Four novel tarantula toxins as selective modulators of voltage-gated sodium channel subtypes.
Bosmans F; Rash L; Zhu S; Diochot S; Lazdunski M; Escoubas P; Tytgat J
Mol Pharmacol; 2006 Feb; 69(2):419-29. PubMed ID: 16267209
[TBL] [Abstract][Full Text] [Related]
4. Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders.
Mantegazza M; Curia G; Biagini G; Ragsdale DS; Avoli M
Lancet Neurol; 2010 Apr; 9(4):413-24. PubMed ID: 20298965
[TBL] [Abstract][Full Text] [Related]
5. The pharmacology of voltage-gated sodium channels in sensory neurones.
Docherty RJ; Farmer CE
Handb Exp Pharmacol; 2009; (194):519-61. PubMed ID: 19655117
[TBL] [Abstract][Full Text] [Related]
6. Voltage-gated Na+ channels in neuropathic pain.
Hargus NJ; Patel MK
Expert Opin Investig Drugs; 2007 May; 16(5):635-46. PubMed ID: 17461737
[TBL] [Abstract][Full Text] [Related]
7. Voltage-gated sodium channels in pain states: role in pathophysiology and targets for treatment.
Dib-Hajj SD; Binshtok AM; Cummins TR; Jarvis MF; Samad T; Zimmermann K
Brain Res Rev; 2009 Apr; 60(1):65-83. PubMed ID: 19150627
[TBL] [Abstract][Full Text] [Related]
8. Voltage-gated sodium channel blockers for the treatment of chronic pain.
Matulenko MA; Scanio MJ; Kort ME
Curr Top Med Chem; 2009; 9(4):362-76. PubMed ID: 19442207
[TBL] [Abstract][Full Text] [Related]
9. Probing gating mechanisms of sodium channels using pore blockers.
Goldschen-Ohm MP; Chanda B
Handb Exp Pharmacol; 2014; 221():183-201. PubMed ID: 24737237
[TBL] [Abstract][Full Text] [Related]
10. Spider-venom peptides that target voltage-gated sodium channels: pharmacological tools and potential therapeutic leads.
Klint JK; Senff S; Rupasinghe DB; Er SY; Herzig V; Nicholson GM; King GF
Toxicon; 2012 Sep; 60(4):478-91. PubMed ID: 22543187
[TBL] [Abstract][Full Text] [Related]
11. Voltage-gated sodium channels: therapeutic targets for pain.
Dib-Hajj SD; Black JA; Waxman SG
Pain Med; 2009 Oct; 10(7):1260-9. PubMed ID: 19818036
[TBL] [Abstract][Full Text] [Related]
12. Animal toxins influence voltage-gated sodium channel function.
Gilchrist J; Olivera BM; Bosmans F
Handb Exp Pharmacol; 2014; 221():203-29. PubMed ID: 24737238
[TBL] [Abstract][Full Text] [Related]
13. Blockers of voltage-gated sodium channels for the treatment of central nervous system diseases.
Tarnawa I; Bölcskei H; Kocsis P
Recent Pat CNS Drug Discov; 2007 Jan; 2(1):57-78. PubMed ID: 18221218
[TBL] [Abstract][Full Text] [Related]
14. Voltage-gated sodium channels and pain.
Priestley T
Curr Drug Targets CNS Neurol Disord; 2004 Dec; 3(6):441-56. PubMed ID: 15578963
[TBL] [Abstract][Full Text] [Related]
15. Voltage-gated sodium channels: mutations, channelopathies and targets.
Andavan GS; Lemmens-Gruber R
Curr Med Chem; 2011; 18(3):377-97. PubMed ID: 21143119
[TBL] [Abstract][Full Text] [Related]
16. Interaction between voltage-gated sodium channels and the neurotoxin, tetrodotoxin.
Lee CH; Ruben PC
Channels (Austin); 2008; 2(6):407-12. PubMed ID: 19098433
[TBL] [Abstract][Full Text] [Related]
17. Voltage-gated sodium channels and hyperalgesia.
Lai J; Porreca F; Hunter JC; Gold MS
Annu Rev Pharmacol Toxicol; 2004; 44():371-97. PubMed ID: 14744251
[TBL] [Abstract][Full Text] [Related]
18. ProTx-I and ProTx-II: gating modifiers of voltage-gated sodium channels.
Priest BT; Blumenthal KM; Smith JJ; Warren VA; Smith MM
Toxicon; 2007 Feb; 49(2):194-201. PubMed ID: 17087985
[TBL] [Abstract][Full Text] [Related]
19. The neuroleptic drug, fluphenazine, blocks neuronal voltage-gated sodium channels.
Zhou X; Dong XW; Priestley T
Brain Res; 2006 Aug; 1106(1):72-81. PubMed ID: 16839522
[TBL] [Abstract][Full Text] [Related]
20. An epilepsy mutation in the sodium channel SCN1A that decreases channel excitability.
Barela AJ; Waddy SP; Lickfett JG; Hunter J; Anido A; Helmers SL; Goldin AL; Escayg A
J Neurosci; 2006 Mar; 26(10):2714-23. PubMed ID: 16525050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
